CARLSBAD, Calif., Oct. 12, 2011 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced the launch of the Ion AmpliSeq™ Cancer Panel, enabling scientists to sequence dozens of genes in cancer research samples using a simple workflow. Mutations are confirmed within just one day, starting with a single-tube reaction and 10 ng of DNA extracted from fixed, frozen or fresh tissue. Novel Ion AmpliSeq™ kits prepare targeted regions for sequencing in 3.5 hours of total time, with under 10 minutes of
hands-on time, just like standard PCR. The method is scalable to hundreds of genes. Current methods require weeks of work to generate hundreds of gene regions via PCR or hybridization-based capture.
This dramatic improvement in time-to-result will accelerate cancer research, enabling even small labs to run thousands of research samples a year. The Ion AmpliSeq™ Cancer Panel sequences 46 cancer-related genes for over 700 known cancer mutations. The panel was chosen in collaboration with leading oncologists and cancer researchers. View a video with an Ion AmpliSeq™ user.
Speed: The Ion AmpliSeq™ Cancer Panel enables researchers to sequence 190 amplicons in one day starting with a 3.5 hour amplification reaction, then Ion OneTouch™ template preparation, and finally a sequencing run that takes just 90 minutes.
Simplicity: The Ion AmpliSeq™ Cancer Panel is the simplest solution because researchers just add DNA to a single tube containing all primers. It's as easy to perform as endpoint PCR, so any trained laboratory technician can do it successfully. The technology is ideal for FFPE or biopsy research samples because it requires only 10 ng of DNA, yet it's sensitive enough to detect variation present in complex research samples at only a 5 percent frequency.
Scalability: Ion AmpliSeq™ technology is highly scalable, accommodating hundreds of genes or DNA regions up to 500 kb in size. It also accommodates a range of budgets. For small projects, researchers can use the Ion 314™ chip for just $99. For larger projects or for barcoding samples, researchers can use the 100 Mb Ion 316™ chip or the 1 Gb Ion 318™ chip, available by the end of 2011. Ion AmpliSeq™ technology is compatible with barcodes and fully configurable in 96 or 384 well plate formats - delivering additional scalability.
Early access customers have reported excellent results with the Ion AmpliSeq™ Cancer Panel:
"While we have only been using Ion AmpliSeq™ Cancer Panels for a short time, we are very pleased with the results," said Dr. Christopher Corless, Medical Director of the Knight Diagnostic Laboratories at Oregon Health and Science University. "We've been able to obtain perfect correlation, in that every mutation we knew about going into the study emerged on the other end of the Ion PGM™ sequencer as an exact match. This technology has enormous potential in clinical research because it's so simple and will enable us to rapidly get more information to our hematologists and oncologists for less money." View a video interview with Dr. Corless.
"The product is remarkably easy to use with very little 'hands on' time," said Marjolijn Ligtenberg, the head of the Laboratory of Tumor Genetics at the Radboud University Nijmegen Medical Centre in The Netherlands. "The amount of required starting material is incredibly small, considering how many mutations can be tested. In our first experiment all KRAS mutations previously identified with TaqMan® Mutation Detection assays and Sanger sequencing were confirmed."
"Next generation sequencing will change the clinical management of the cancer patient," said Prof Pierre Laurent-Puig, who runs the Clinical Oncogenetic Unit in the Department of Genetics at the Paris - Descartes University Medical School. "The Ion AmpliSeq™ Cancer Panel could help us fill some existing gaps between classical mutation detection and exome sequencing. Our testing of this new technology has allowed detection of KRAS and EGFR alterations in colon and lung cancer research samples preserved in paraffin embedded tissue."
"This next generation sequencing technology permits deep sequencing of a panel of mutations at the same time. It can detect mutations at frequencies as low as 5 percent with short turn around time and low cost," said Marilyn M. Li, M.D., director of the Cancer Genetics Laboratory at Baylor College of Medicine. "This could be an ideal solution for us and we see a great potential for diagnostic applications."
By merging multiplex PCR with massively parallel Ion semiconductor sequencing, the Ion AmpliSeq™ Cancer Panel generates data needed to advance oncology research and improve life.
For Research Use Only. Not intended for any animal or human therapeutic or diagnostic use.
The content provided herein may relate to products that have not been officially released and is subject to change without notice.
About Life Technologies (www.lifetechnologies.com)
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the
world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan® products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website:
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar
expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Ion Torrent Contact
SOURCE Life Technologies Corporation